FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912374030> ?p ?o ?g. }

• W2912374030 endingPage "1260" @default.
• W2912374030 startingPage "1249" @default.
• W2912374030 abstract "Purpose To describe the course of intermittent exotropia (IXT) in children followed up without treatment for 3 years. Design Observation arm from randomized trial of short-term occlusion versus observation. Participants One hundred eighty-three children 3 to 10 years of age with previously untreated IXT and 400 seconds of arc (arcsec) or better near stereoacuity. Methods Participants were to receive no treatment unless deterioration criteria were met at a follow-up visit occurring at 3 months, 6 months, or 6-month intervals thereafter for 3 years. Main Outcome Measures The primary outcome was deterioration by 3 years, defined as meeting motor criterion (constant exotropia ≥10 prism diopters [Δ] at distance and near) or near stereoacuity criterion (≥2-octave decrease from best previous measure). For the primary analysis, participants also were considered to have deteriorated if treatment was prescribed without meeting either deterioration criterion. Results The cumulative probability of protocol-specified deterioration by 3 years was 15% (95% confidence interval, 10%–22%), but that was likely an overestimate, partly because of misclassification. Among 25 deteriorations, 2 met motor deterioration, 11 met stereoacuity deterioration, and 12 started treatment without meeting either criteria (7 for social concern, 1 for diplopia, 4 for other reasons). Among the 132 participants who completed the 3-year visit and had not been treated during the study, only 1 (<1%) met motor or stereoacuity deterioration criteria at 3 years. Of the 4 participants completing the 3-year visit who met deterioration criteria previously and had not started treatment, none still met deterioration criteria. Between the baseline and 3-year examination for these 132 patients, improvement occurred in distance and near stereoacuity (mean improvement, 0.14 and 0.14 logarithm of arcsec; P ≤ 0.001 and P ≤ 0.001, respectively), distance exotropia control (mean improvement, 0.6 points; P ≤ 0.001), and distance exodeviation magnitude (mean improvement, 2.2 Δ; P = 0.002). Conclusions Among children 3 to 10 years of age with IXT for whom surgery was not considered to be the immediately necessary treatment, stereoacuity deterioration or progression to constant exotropia over 3 years was uncommon, and exotropia control, stereoacuity, and magnitude of deviation remained stable or improved slightly. To describe the course of intermittent exotropia (IXT) in children followed up without treatment for 3 years. Observation arm from randomized trial of short-term occlusion versus observation. One hundred eighty-three children 3 to 10 years of age with previously untreated IXT and 400 seconds of arc (arcsec) or better near stereoacuity. Participants were to receive no treatment unless deterioration criteria were met at a follow-up visit occurring at 3 months, 6 months, or 6-month intervals thereafter for 3 years. The primary outcome was deterioration by 3 years, defined as meeting motor criterion (constant exotropia ≥10 prism diopters [Δ] at distance and near) or near stereoacuity criterion (≥2-octave decrease from best previous measure). For the primary analysis, participants also were considered to have deteriorated if treatment was prescribed without meeting either deterioration criterion. The cumulative probability of protocol-specified deterioration by 3 years was 15% (95% confidence interval, 10%–22%), but that was likely an overestimate, partly because of misclassification. Among 25 deteriorations, 2 met motor deterioration, 11 met stereoacuity deterioration, and 12 started treatment without meeting either criteria (7 for social concern, 1 for diplopia, 4 for other reasons). Among the 132 participants who completed the 3-year visit and had not been treated during the study, only 1 (<1%) met motor or stereoacuity deterioration criteria at 3 years. Of the 4 participants completing the 3-year visit who met deterioration criteria previously and had not started treatment, none still met deterioration criteria. Between the baseline and 3-year examination for these 132 patients, improvement occurred in distance and near stereoacuity (mean improvement, 0.14 and 0.14 logarithm of arcsec; P ≤ 0.001 and P ≤ 0.001, respectively), distance exotropia control (mean improvement, 0.6 points; P ≤ 0.001), and distance exodeviation magnitude (mean improvement, 2.2 Δ; P = 0.002). Among children 3 to 10 years of age with IXT for whom surgery was not considered to be the immediately necessary treatment, stereoacuity deterioration or progression to constant exotropia over 3 years was uncommon, and exotropia control, stereoacuity, and magnitude of deviation remained stable or improved slightly." @default.
• W2912374030 created "2019-02-21" @default.
• W2912374030 creator A5018491228 @default.
• W2912374030 creator A5021621871 @default.
• W2912374030 creator A5022813531 @default.
• W2912374030 creator A5038357712 @default.
• W2912374030 creator A5042560384 @default.
• W2912374030 creator A5044156792 @default.
• W2912374030 creator A5068651869 @default.
• W2912374030 creator A5078414657 @default.
• W2912374030 creator A5082946134 @default.
• W2912374030 creator A5090967921 @default.
• W2912374030 creator A5091742600 @default.
• W2912374030 date "2019-09-01" @default.
• W2912374030 modified "2023-10-16" @default.
• W2912374030 title "Three-Year Observation of Children 3 to 10 Years of Age with Untreated Intermittent Exotropia" @default.
• W2912374030 cites W1977069225 @default.
• W2912374030 cites W1994759467 @default.
• W2912374030 cites W2006238033 @default.
• W2912374030 cites W2015282460 @default.
• W2912374030 cites W2023641660 @default.
• W2912374030 cites W2023758895 @default.
• W2912374030 cites W2056100782 @default.
• W2912374030 cites W2063206843 @default.
• W2912374030 cites W2072553967 @default.
• W2912374030 cites W2072798312 @default.
• W2912374030 cites W2081980936 @default.
• W2912374030 cites W2111700425 @default.
• W2912374030 cites W2112945940 @default.
• W2912374030 cites W2128290637 @default.
• W2912374030 cites W2150416883 @default.
• W2912374030 cites W2159759971 @default.
• W2912374030 cites W2161550071 @default.
• W2912374030 cites W2161561166 @default.
• W2912374030 cites W2163265703 @default.
• W2912374030 doi "https://doi.org/10.1016/j.ophtha.2019.01.015" @default.
• W2912374030 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6660425" @default.
• W2912374030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30690128" @default.
• W2912374030 hasPublicationYear "2019" @default.
• W2912374030 type Work @default.
• W2912374030 sameAs 2912374030 @default.
• W2912374030 citedByCount "27" @default.
• W2912374030 countsByYear W29123740302019 @default.
• W2912374030 countsByYear W29123740302020 @default.
• W2912374030 countsByYear W29123740302021 @default.
• W2912374030 countsByYear W29123740302022 @default.
• W2912374030 countsByYear W29123740302023 @default.
• W2912374030 crossrefType "journal-article" @default.
• W2912374030 hasAuthorship W2912374030A5018491228 @default.
• W2912374030 hasAuthorship W2912374030A5021621871 @default.
• W2912374030 hasAuthorship W2912374030A5022813531 @default.
• W2912374030 hasAuthorship W2912374030A5038357712 @default.
• W2912374030 hasAuthorship W2912374030A5042560384 @default.
• W2912374030 hasAuthorship W2912374030A5044156792 @default.
• W2912374030 hasAuthorship W2912374030A5068651869 @default.
• W2912374030 hasAuthorship W2912374030A5078414657 @default.
• W2912374030 hasAuthorship W2912374030A5082946134 @default.
• W2912374030 hasAuthorship W2912374030A5090967921 @default.
• W2912374030 hasAuthorship W2912374030A5091742600 @default.
• W2912374030 hasBestOaLocation W29123740302 @default.
• W2912374030 hasConcept C126322002 @default.
• W2912374030 hasConcept C141071460 @default.
• W2912374030 hasConcept C168260308 @default.
• W2912374030 hasConcept C168563851 @default.
• W2912374030 hasConcept C187212893 @default.
• W2912374030 hasConcept C2776864138 @default.
• W2912374030 hasConcept C2778207058 @default.
• W2912374030 hasConcept C2778257484 @default.
• W2912374030 hasConcept C2780581723 @default.
• W2912374030 hasConcept C2908550172 @default.
• W2912374030 hasConcept C44249647 @default.
• W2912374030 hasConcept C71924100 @default.
• W2912374030 hasConceptScore W2912374030C126322002 @default.
• W2912374030 hasConceptScore W2912374030C141071460 @default.
• W2912374030 hasConceptScore W2912374030C168260308 @default.
• W2912374030 hasConceptScore W2912374030C168563851 @default.
• W2912374030 hasConceptScore W2912374030C187212893 @default.
• W2912374030 hasConceptScore W2912374030C2776864138 @default.
• W2912374030 hasConceptScore W2912374030C2778207058 @default.
• W2912374030 hasConceptScore W2912374030C2778257484 @default.
• W2912374030 hasConceptScore W2912374030C2780581723 @default.
• W2912374030 hasConceptScore W2912374030C2908550172 @default.
• W2912374030 hasConceptScore W2912374030C44249647 @default.
• W2912374030 hasConceptScore W2912374030C71924100 @default.
• W2912374030 hasFunder F4320332161 @default.
• W2912374030 hasFunder F4320337350 @default.
• W2912374030 hasIssue "9" @default.
• W2912374030 hasLocation W29123740301 @default.
• W2912374030 hasLocation W29123740302 @default.
• W2912374030 hasLocation W29123740303 @default.
• W2912374030 hasOpenAccess W2912374030 @default.
• W2912374030 hasPrimaryLocation W29123740301 @default.
• W2912374030 hasRelatedWork W1184753824 @default.
• W2912374030 hasRelatedWork W2047590128 @default.
• W2912374030 hasRelatedWork W2069168379 @default.
• W2912374030 hasRelatedWork W2140727486 @default.
• W2912374030 hasRelatedWork W2149589491 @default.
• W2912374030 hasRelatedWork W2376907910 @default.

• next